WHO Pharmaceuticals Newsletter No. 5, 2015

OMS, 22 de octubre de 2015

Tabla de contenidos

Regulatory Matters

• Amantadine hydrochloride
• Asunaprevir and daclatasvir
• Azithromycin hydrate
• Canagliflozin
• Clozapine
• Deferasirox
• Fingolimod
• Hydroxyzine-containing medicines
• Infliximab
• Ingenol mebutate gel
• Laninamivir octanoate and zanamivir
• Memantine hydrochloride
• Nivolumab
• Panitumumab
• Pomalidomide
• Proton pump inhibitors
• Risperidone
• Sodium-glucose co-transporter 2 (SGLT2) inhibitors
• Sterile talc
• Treanda® Injection

Safety of medicines

• Bortezomib
• Brintellix® (vortioxetine) and Brilinta® (ticagrelor)
• DPP-4 Inhibitors for Type 2 Diabetes
• Eltrombopag
• Etanercept
• Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI)
• Pseudoephedrine and ephedrine
• Rivaroxaban
• Tramadol oral drops

Signal

• Dextromethorphan and serious neurological disorders in children
• Olanzapine and accidental drug intake by children
• Temozolomide and Oesophagitis

Feature

• WHO-UMC-HSA Inter-Regional Pharmacovigilance Training, Singapore, 30 September -2 October
• 2015
• The World Health Organization organizes an integrated vigilance workshop for Eastern Mediterranean regional countries in Rabat
• Building Pharmacovigilance in Member States of Central African Economic Monetary Community (CEMAC)

Disponible en http://bit.ly/1RYJ2M2